In this article

LLY

Follow your favorite stocks CREATE FREE ACCOUNT

Eli Lilly on Thursday hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster weight loss and diabetes drugs.

The company raised its fiscal 2025 sales guidance to $60 billion to $62 billion, from a previous outlook of $58 billion to $61 billion on underlying strength across its business. The pharmaceutical giant also expects its adjusted fiscal 2025 earnings to come in between $21.75 and $23, up from previous guidance of $20.78 to $22.28 per share.

Eli Lilly said the guidance reflects President Donald Trump 's existing tariffs as of Aug. 7, but does not include his planned levies on pharmaceuticals imported into the U.S.

Also on Thursday, Eli

See Full Page